SSTR2 receptor states and cellular metabolism modulate 177Lu-DOTATATE binding affinity

Sara Lundsten Salomonsson, Pleun AM Engbers, Julie Nonnekens, Sina Bondza · 2026

Read SSTR2 receptor states and cellular metabolism modulate 177Lu-DOTATATE binding affinity by Sara Lundsten Salomonsson, Pleun AM Engbers, Julie Nonnekens, Sina Bondza (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13625453.txt.

Description

Sara Lundsten Salomonsson and co-authors study in 2026 how a radioactive cancer drug binds to its target on live tumor cells. The drug is 177Lu-DOTATATE. Its target is somatostatin receptor 2, found on neuroendocrine tumors. Real-time binding assays found two groups of binding. The groups differed mainly in how long the drug stayed bound.

In one group, binding was tight, in the sub-nanomolar range. That binding involved receptors coupled to G proteins. In the other group, binding was weaker, in the nanomolar range. Those receptors were not coupled. Longer contact with the drug cut how much stayed bound. This suggests the receptors shift their coupling state over time. Both the drug and its target built up inside the cells. Drug with no label could push stored drug back out. That shows a constant turnover of the drug.

Catalog record

CREATORSara Lundsten Salomonsson, Pleun AM Engbers, Julie Nonnekens, Sina Bondza
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE42 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13625453

Browse the full library · About the Tower of Babel